Abstract:4156 Background: The hedgehog pathway plays a critical role in embryonic development, tissue polarity and carcinogenesis. It is estimated that activation of this pathway is associated with almost all basal cell carcinomas and in nearly 30% of non-skin cancers. Whereas mutations of human homologue of patched 1 (PTCH1), smoothened (SMO) or suppressor of fused [Su(Fu)] contribute to the development of BCCs and medulloblastomas, whereas elevated expression of the ligands- hedgehog molecules may be responsible for activation of hedgehog signaling in prostate, breast, lung and gastrointestinal cancers. However, the molecular basis for SMO signaling regulation, the essential event in pathway activation, remains unclear. Therefore, identification of novel regulators of SMO will further our understanding of hedgehog-mediated carcinogenesis. Results: Through yeast two hybrid screening using SMO as bait, we identified a Smooothened Interacting Protein, SIP. In cultured cells, we showed that SIP co-immunoprecipitated reciprocally with SMO. Using GST pull-down studies, we showed that the cytoplasmic tail of SMO is responsible for the interaction with SIP. We found that stability of SMO protein, but not Gli1 protein, can be enhanced with ectopic expression of SIP in a dose-dependent manner. To demonstrate whether inactivation of SIP is sufficient to inhibit growth of cancer cells with activated hedgehog signaling, we treated cancer cell lines with SIP siRNA or control siRNA and measured DNA synthesis and softagar growth. We found that SIP siRNA inhibited DNA synthesis and softagar growth of PLC/PRF/5 cells, which have activated hedgehog signaling, but had no effects on HepG2 cells, which have no detectable hedgehog signaling. Conclusion: We have identified a novel regulator of SMO, SIP. We find that SMO interacts with SIP through its c-terminal tail. The protein stability of SMO is enhanced by the presence of SIP. Inactivation of SIP by specific siRNA, just like SMO antagonist cyclopamine, reduced DNA synthesis and cell growth of cancer cells with activated hedgehog signaling. Thus, targeted inhibition of SIP may have significant implications in cancer therapeutics.

Converse Conformational Control of Smoothened Activity by Structurally Related Small Molecules

Hedgehog Regulates Smoothened Activity by Inducing a Conformational Switch

Discovery of Potent and Novel Smoothened Antagonists Via Structure-Based Virtual Screening and Biological Assays.

Transducing the Hedgehog Signal Across the Plasma Membrane

Regulation of Smoothened Phosphorylation and High-Level Hedgehog Signaling Activity by a Plasma Membrane Associated Kinase

Mechanisms of Smoothened Regulation in Hedgehog Signaling

Design, Synthesis, and Structure–activity-Relationship of Tetrahydrothiazolopyridine Derivatives As Potent Smoothened Antagonists

Smoothened Transduces Hedgehog Signal by Physically Interacting with Costal2/Fused Complex Through Its C-terminal Tail.

Small Molecule Antagonists in Distinct Binding Modes Inhibit Drug-Resistant Mutant of Smoothened.

Scaffold Hopping Approach to a New Series of Smoothened Antagonists

Structural Optimization on a Virtual Screening Hit of Smoothened Receptor.

Novel-smoothened Inhibitors for Therapeutic Targeting of Naïve and Drug-Resistant Hedgehog Pathway-Driven Cancers.

Solubilization, purification, and ligand binding characterization of G protein-coupled receptor SMO in native membrane bilayer using styrene maleic acid copolymer

Hedgehog Signalling Activity of Smoothened Requires Phosphorylation by Protein Kinase A and Casein Kinase I

Identification of a Novel Regulator for Smoothened Signaling in Human Cancers

Pitchfork And Gprasp2 Target Smoothened To The Primary Cilium For Hedgehog Pathway Activation

Small-molecule modulators of the Sonic Hedgehog signaling pathway

Structure of the human smoothened receptor bound to an antitumour agent

Effect of Mutations on Drug Resistance of Smoothened Receptor Toward Inhibitors Probed by Molecular Modeling

Deciphering the Allosteric Effect of Antagonist Vismodegib on Smoothened Receptor Deactivation Using Metadynamics Simulation.

Crystal Structure of a Multi-Domain Human Smoothened Receptor in Complex with a Super Stabilizing Ligand